Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 11/20 | 0.49 |
| ▸ | ITGA2B | P08514 | 11/20 | 0.49 |
| ▸ | ITGAV | P06756 | 1/20 | 0.46 |
| ▸ | CTSS | P25774 | 4/20 | 0.46 |
| ▸ | CTSK | P43235 | 4/20 | 0.46 |
| ▸ | CTSL | P07711 | 1/20 | 0.46 |
| ▸ | CTSB | P07858 | 1/20 | 0.46 |
| ▸ | TACR1 | P25103 | 1/20 | 0.44 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.44 |
| ▸ | CAPN2 | P17655 | 1/20 | 0.44 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3733061 | 0.98 | ITGB3 (0.52) | ITGB3ITGA2BITGAVCTSSCTSK | |
| SCHEMBL3738549 | 0.93 | ITGB3 (0.51) | ITGB3ITGA2BITGAVCTSSCTSK | |
| SCHEMBL3740554 | 0.93 | ITGB3 (0.51) | ITGB3ITGA2BITGAVCTSSCTSK | |
| SCHEMBL3732066 | 0.89 | ITGB3 (0.47) | ITGB3ITGA2BITGAVCTSSCTSK | |
| SCHEMBL5516497 | 0.88 | ITGB3 (0.54) | ITGB3ITGA2BITGAVCTSSCTSK | |
| SCHEMBL5516504 | 0.88 | ITGB3 (0.54) | ITGB3ITGA2BITGAVCTSSCTSK | |
| SCHEMBL3736086 | 0.88 | PTPN1 (0.55) | — | |
| SCHEMBL3732019 | 0.87 | PTPN1 (0.48) | — | |
| SCHEMBL3732061 | 0.86 | ITGB3 (0.52) | ITGB3ITGA2BITGAVCTSSCTSK | |
| SCHEMBL3732062 | 0.86 | ITGB3 (0.52) | ITGB3ITGA2BITGAVCTSSCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7829737-B2 | Protein tyrosine phosphatase inhibitors and methods of use thereof | CEPTYR, INC. (US) | 2010-11-09 | — | — | US | disclosed |
| US-20090131374-A1 | PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | CEPTYR, INC. (US) | 2009-05-21 | — | — | US | disclosed |
| US-7504389-B2 | Protein tyrosine phosphatase inhibitors and methods of use thereof | CEPTYR, INC. (US) | 2009-03-17 | — | — | US | disclosed |
| US-20080161592-A1 | PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | CEPTYR, INC. (US) | 2008-07-03 | — | — | US | disclosed |
| US-20060142250-A1 | Protein tyrosine phosphatase inhibitors and methods of use thereof | FALCON TECHNOLOGY PARTNERS L.P. | 2006-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080161592-A1 | PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | PPM1B, PTPN1, PTPN5 | ITGB3 4528/4885ITGA2B 3660/4885ITGAV 4827/4885 |
| US-20060142250-A1 | Protein tyrosine phosphatase inhibitors and methods of use thereof | PPM1B, PTPN1, PTPN5 | ITGB3 4528/4885ITGA2B 3660/4885ITGAV 4827/4885 |
| US-20090131374-A1 | PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | PPM1B, PTPN1, PTPN5 | ITGB3 4528/4885ITGA2B 3660/4885ITGAV 4827/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.